Dr. Lal PathLabs CEO Bharath Uppilliappan steps down

Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer

Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis

Amita Sharma redesignated As COO- API at Morepen Lab

Sharma joined the Morepen Lab in 2004

Strides receives USFDA approval for Gabapentin Tablets

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months

Biocon appoints Vishal Nayyar as Head – SCM and Amit Kaptain as Head Commercials - API

Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg

The product will be launched in March 2024

Cabinet approves post of director for National Institute for One Health

The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness

Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers

BHL will undertake the development and supply of these molecules

Chemex Global inaugurates state-of-the-art API plant in Guwahati

The plant will drive pharmaceutical innovation in the Northeastern India